Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data

2002 ◽  
Author(s):  
Arash Naeim
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Treatment ◽  
Cataract Surgery ◽  
Healthcare Cost ◽  
Older Patients ◽  
Breast Cancer Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Treatment Data

scholarly journals ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country

2014 ◽  
Vol 16 (2) ◽  
pp. 270-280 ◽  
Author(s):  
Mario García Molina ◽  
Liliana Alejandra Chicaíza-Becerra ◽  
Liliana Alejandra Chicaíza-Becerra ◽  
Carlos Castañeda ◽  
Carlos Castañeda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Treatment ◽  
Developing Country ◽  
Metastatic Breast ◽  
Breast Cancer Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

Trastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 628-628 ◽  
Author(s):  
J. Norum ◽  
J. A. Olsen
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Discount Rate ◽  
Breast Cancer Treatment ◽  
Cost Effectiveness Analysis ◽  
Survival Gain ◽  
Effectiveness Analysis ◽  
Adjuvant Breast Cancer

628 Background: Trastuzumab has shown activity in patients with early breast cancer that overexpress HER2. However, significant resources have to be allocated to finance this therapy, therefore its cost-effectiveness is called for and treatment’s value for money should be calculated. We aimed to evaluate the marginal cost effectiveness of trastuzumab in adjuvant treatment of HER2 positive early breast cancer in a model based cost-effectiveness-analysis (CEA). Methods: A breast cancer treatment model was set up. Societal costs were calculated according to Norwegian prices as in September 2005 and converted to Euros at the rate of 1Euro = 7.81 NOK. Life expectancy data were based on the literature and prolonged according to qualified guess (10% and 20% improved overall survival (OS). The comparator was the present practice, the FEC100 regimen alone. The human capital approach was employed and a sensitivity analysis was added. Results: The median raised cost per patient treated was calculated at Euro16,713 - 35,714. The yielding cost per life year saved was in the range between Euro 5,571 and 32,616, depending on survival gain (10% or 20% improved OS) and discount rate (0% or 3%) employed. The sensitivity analyses documented survival gain, discount rate and price of trastuzumab the major factors influencing cost-effectiveness ratio. Conclusion: The economic evaluation indicates trastuzumab cost effective in adjuvant breast cancer treatment. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document